Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Sonnet BioTherapeutics stock | $1.55

Learn how to easily invest in Sonnet BioTherapeutics stock.

Sonnet BioTherapeutics Holdings, Inc
NASDAQ: SONN - USD
BIOTECHNOLOGY
$1.02
-$0.01 (-0.65%)

Sonnet BioTherapeutics Holdings, Inc is a biotechnology business based in the US. Sonnet BioTherapeutics shares (SONN) are listed on the NASDAQ and all prices are listed in US Dollars. Sonnet BioTherapeutics employs 9 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Sonnet BioTherapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SONN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Sonnet BioTherapeutics stock price (NASDAQ: SONN)

Use our graph to track the performance of SONN stocks over time.

Sonnet BioTherapeutics shares at a glance

Information last updated 2021-07-28.
Latest market close$1.55
52-week range$1.00 - $4.29
50-day moving average $1.40
200-day moving average $2.04
Wall St. target price$8.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-66.46

Buy Sonnet BioTherapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sonnet BioTherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sonnet BioTherapeutics price performance over time

Historical closes compared with the close of $1.55 from 2021-05-28

1 week (2021-07-25) N/A
1 month (2021-07-02) 2.65%
3 months (2021-05-05) -17.99%
6 months (2021-02-01) N/A
1 year (2020-08-01) N/A
2 years (2019-08-01) N/A
3 years (2018-08-01) N/A
5 years (2016-08-01) N/A

Sonnet BioTherapeutics financials

Gross profit TTM $0
Return on assets TTM -356.91%
Return on equity TTM -27822.18%
Profit margin 0%
Book value $0.10
Market capitalisation $24 million

TTM: trailing 12 months

Shorting Sonnet BioTherapeutics shares

There are currently 2.1 million Sonnet BioTherapeutics shares held short by investors – that's known as Sonnet BioTherapeutics's "short interest". This figure is 48.7% up from 1.4 million last month.

There are a few different ways that this level of interest in shorting Sonnet BioTherapeutics shares can be evaluated.

Sonnet BioTherapeutics's "short interest ratio" (SIR)

Sonnet BioTherapeutics's "short interest ratio" (SIR) is the quantity of Sonnet BioTherapeutics shares currently shorted divided by the average quantity of Sonnet BioTherapeutics shares traded daily (recently around 808893.10344828). Sonnet BioTherapeutics's SIR currently stands at 2.61. In other words for every 100,000 Sonnet BioTherapeutics shares traded daily on the market, roughly 2610 shares are currently held short.

However Sonnet BioTherapeutics's short interest can also be evaluated against the total number of Sonnet BioTherapeutics shares, or, against the total number of tradable Sonnet BioTherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sonnet BioTherapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Sonnet BioTherapeutics shares in existence, roughly 100 shares are currently held short) or 0.1133% of the tradable shares (for every 100,000 tradable Sonnet BioTherapeutics shares, roughly 113 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sonnet BioTherapeutics.

Find out more about how you can short Sonnet BioTherapeutics stock.

Sonnet BioTherapeutics share dividends

We're not expecting Sonnet BioTherapeutics to pay a dividend over the next 12 months.

Have Sonnet BioTherapeutics's shares ever split?

Sonnet BioTherapeutics's shares were split on a 1:26 basis on 1 April 2020. So if you had owned 26 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sonnet BioTherapeutics shares – just the quantity. However, indirectly, the new 2500% higher share price could have impacted the market appetite for Sonnet BioTherapeutics shares which in turn could have impacted Sonnet BioTherapeutics's share price.

Sonnet BioTherapeutics overview

Sonnet BioTherapeutics Holdings, Inc. , an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding (FHAB) technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced peripheral neuropathy. The company is also developing SON-081, a low dose IL-6 for the treatment of patients with diabetic peripheral neuropathy and is under phase I trials; SON-1010, a FHAB derived compound, which utilizes a human version of Interleukin-12 (IL-12) is under pre-clinical trial, as well as SON-1210, a bi-specific construct that combines FHAB with IL-12 and human Interleukin-15 for the treatment of solid tumor is under pre-clinical trial. In addition, it develops SON-2014, a bi-specific combination of granulocyte-macrophage colony stimulating factor and Interleukin-18 for the treatment of cancer; and SON-3015, a bi-specific combination of anti-IL6 and anti-tumor growth factor beta for tumor and bone metastases. Sonnet BioTherapeutics Holdings, Inc.

Stocks similar to Sonnet BioTherapeutics

Frequently asked questions

What percentage of Sonnet BioTherapeutics is owned by insiders or institutions?
Currently 8.801% of Sonnet BioTherapeutics shares are held by insiders and 3.437% by institutions.
How many people work for Sonnet BioTherapeutics?
Latest data suggests 9 work at Sonnet BioTherapeutics.
When does the fiscal year end for Sonnet BioTherapeutics?
Sonnet BioTherapeutics's fiscal year ends in December.
Where is Sonnet BioTherapeutics based?
Sonnet BioTherapeutics's address is: 100 Overlook Center, Princeton, NJ, United States, 08540
What is Sonnet BioTherapeutics's ISIN number?
Sonnet BioTherapeutics's international securities identification number is: US83548R1059
What is Sonnet BioTherapeutics's CUSIP number?
Sonnet BioTherapeutics's Committee on Uniform Securities Identification Procedures number is: 15930P206

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site